Art. -Nr.: HY-N2541

Gymnemic acid I

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Gymnemic acid I is a bioactive triterpene saponin found in Gymnema sylvestre. Gymnemic acid I is an antisweetness inhibitor via human sweet receptor type 1 receptor 2 (T1R2) and T1R3. Gymnemic acid I is a ribosomal protein biosynthesis inhibitor. Gymnemic acid I has antidiabetic effects. Gymnema acid I induces autophagy-protected MIN-6 cells from apoptosis under high glucose stress by inhibiting the phosphorylation activity of mTOR.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.59%
CAS. Nr.: 122168-40-5
Formel: C₄₃H₆₆O₁₄
Molecular Weight:806.98

Speicherung:

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Gymnemic acid I Chemical Structure

CAS. Nr.: 122168-40-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle mTOR Isoform-spezifische Produkte anzeigen :

In Vitro

In ribosomes from rabbit reticulocytes, Gymnemic acid I (1, 10, and 100 μM) decreases the luciferase translation in a concentration-dependent manner^[1].
Gymnemic acid I (5 μg/mL; 36 hr) decreases the apoptosis under the high glucose stress^[2].
Gymnemic acid I (5 μg/mL; 36 hr) increases the number of autophagosome and the ratio of light chain 3-I (LC3-I)/LC3-II in MIN-6 cells under the normal or high glucose stress. Gymnemic acid I induces autophagy flux and inhibited the phosphorylation of mTOR and ribosomal protein S6 kinase β-1 (p70 S6K/S6K1), which is a substrate of mTOR. Gymnemic acid I decreases the rate of apoptosis and the activity of caspase-3 under the high glucose stress^[2]. x

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[2]

Cell Line:

MIN-6 cells induced by high glucose
Concentration:

5 μg/mL
Incubation Time:

36 hr
Result:

Protected cells from high glucose induced apoptosis.

Cell Autophagy Assay^[2]

Cell Line:

MIN-6 cells induced by high glucose
Concentration:

5 μg/mL
Incubation Time:

36 hr
Result:

The number of autophagosome per cell, the ratio of LC3-II/LC3-I and the degradation of SQSTM1/p62 were increased.

Western Blot Analysis^[2]

Cell Line:

MIN-6 cells induced by high glucose
Concentration:

5 μg/mL
Incubation Time:

36 hr
Result:

Inhibited the serine70 phosphorylation of S6K and serine 2448 phosphorylation of mTOR.

Chemical Information

CAS. Nr. 122168-40-5
Appearance Solid
Molecular Weight 806.98
Formel C₄₃H₆₆O₁₄
Color White to light yellow
SMILES

O[C@H]([C@H]([C@@H]([C@@H](C(O)=O)O1)O)O)[C@@H]1O[C@@H]2CC[C@]3(C)[C@@]4([H])CC=C5[C@]6([H])CC(C)(C)[C@H](OC(/C(C)=C/C)=O)[C@@H](O)[C@@](COC(C)=O)6[C@H](O)C[C@](C)5[C@@](C)4CC[C@]([H])3[C@@]2(C)CO
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

J Ethnopharmacol

Multi-omics characterization of glucose-lipid metabolic remodeling associated with Gymnema sylvestre (Retz.) R.Br. ex Sm. treatment in a type 2 diabetic mouse model. [Abstract]

2026 Jun 20:371:122083. PMID: 42323059

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (61.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2392 mL

6.1959 mL

12.3919 mL

5 mM

0.2478 mL

1.2392 mL

2.4784 mL

10 mM

0.1239 mL

0.6196 mL

1.2392 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.25 mg/mL (1.55 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.25 mg/mL (1.55 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Capolupo A, et al. Determination of Gymnemic Acid I as a Protein Biosynthesis Inhibitor Using Chemical Proteomics. J Nat Prod. 2017 Apr 28;80(4):909-915. [Content Brief]

[2]. Wu Y, et al. Gymnemic acid I triggers mechanistic target of rapamycin-mediated β cells cytoprotection through the promotion of autophagy under high glucose stress. J Cell Physiol. 2019 Jun;234(6):9370-9377. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.2392 mL	6.1959 mL	12.3919 mL	30.9797 mL
	5 mM	0.2478 mL	1.2392 mL	2.4784 mL	6.1959 mL
	10 mM	0.1239 mL	0.6196 mL	1.2392 mL	3.0980 mL
	15 mM	0.0826 mL	0.4131 mL	0.8261 mL	2.0653 mL
	20 mM	0.0620 mL	0.3098 mL	0.6196 mL	1.5490 mL
	25 mM	0.0496 mL	0.2478 mL	0.4957 mL	1.2392 mL
	30 mM	0.0413 mL	0.2065 mL	0.4131 mL	1.0327 mL
	40 mM	0.0310 mL	0.1549 mL	0.3098 mL	0.7745 mL
	50 mM	0.0248 mL	0.1239 mL	0.2478 mL	0.6196 mL
	60 mM	0.0207 mL	0.1033 mL	0.2065 mL	0.5163 mL

Keywords

Gymnemic acid I

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Gymnemic acid I

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Anti-diabetic Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Terpenoids Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Apoptosis Compound Library

GPCR/G Protein Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Autophagy Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) Gymnemic acid I

Alle mTOR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Gymnemic acid I Related Classifications

HY-N2541 Related Classifications